A study suggests that antibiotic use within one month of immune checkpoint inhibitor treatment may undermine survival in ...

Highlights of BioNTech’s oncology programs to be presented at AACR 2025: ...

DelveInsight's "Metastatic Cutaneous Squamous Cell Cancer Market Insights, Epidemiology, and Market Forecast- 2032" report ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Panelists discuss how, as new data on cemiplimab and other checkpoint inhibitors emerge, the treatment pathway for cancers ...

Panelists discuss how, cemiplimab, a PD-1 inhibitor, has shown promise as a second-line therapy for advanced NSCLC after ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, ...

Meredith McKean, MD, MPH, discusses the background and goals from the recent long-term follow-up of a phase 1 study evaluating the combination of fianlimab and cemiplimab in advanced melanoma.

In solid tumors, the tumor microenvironment (TME) is a complex mix of tumor, immune, stromal cells, fibroblasts, and the extracellular matrix. Cytotoxic T lymphocytes (CTLs) constitute a fraction of ...